ADMA vs MRK
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
ADMA's Piotroski F-Score of 3/9 indicates weak financial health, signaling distress risk despite strong profitability metrics. The company trades at a high P/E of 25.25 and Price/Sales of 7.07, significantly above sector averages, suggesting overvaluation. While gross and operating margins are impressive (57.38% and 45.09%), earnings have collapsed YoY by 52.8%, undermining growth credibility. Insider selling totaling $1.58M in the last six months, including multiple large sales by the CEO, reinforces bearish sentiment. The Graham Number of $5.21 and intrinsic value of $4.2 suggest deep undervaluation, but the current price of $15.15 reflects a premium driven by speculative growth expectations rather than fundamentals.
MRK shows neutral fundamentals based on deterministic rules. Financial strength is weak (F-Score 3/9). Mixed signals with both opportunities and risks present.
Compare Another Pair
Related Comparisons
ADMA vs MRK: Head-to-Head Comparison
This page compares ADMA Biologics, Inc. (ADMA) and Merck & Co., Inc. (MRK) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.